OMB No. 0651-0011 Page 1 of 4

* INFORMATION		Atty. Docket No.: 235.0006 0102		Serial	Serial No.: Unknown				
D	ISCL	OSURE	Confirmation No.:						
STATEMENT		Applicant(s): Peter C. Ruenitz							
		Fili	ing Date: On	Even Date Herewith	Grou	Group: 1623			
	U.S. PATENT DOCUMENTS								
Examiner Initial		Document Numbe	r	Date	Name	Class	SubClass		Date If priate
LCM		2,914,563		11/24/59	Allen et al.	260	570		
LCM		3,883,513		05/13/75	Hess et al.	260	240	P	=
LCM		4,522,811		06/11/85	Eppstein et al.	514	2		E.
LCM		4,894,373		01/16/90	Young	5/4	239.2		
LCM		4,938,949		07/03/90	Borch et al.	54 24	239/3	PO.	= 5
LCM		5,189,212		02/23/93	Ruenitz	562	584	20 8	
LCM		5,428,181		06/27/95	Sugioka et al.	552	506	50	
LCM		5,466,815		11/14/95	Enhsen et al.	548	252		
		FO	ORE	IGN PATEN	NT DOCUMENTS				
		Document Numbe	r	Date	Country	Class	SubClass	Trans	lation No
		NONE				 		Yes	140
	<u> </u>	110112							
C	THE	R DOCUMENTS	S (In	cluding Aut	hors, Title, Date, Pe	rtinent F	apers, et	c.)	
LCM		Bignon et al., "Effect of Triphenylacrylonitrile Derivatives on Estradiol-Receptor Binding and on Human Breast Cancer Cell Growth," J. Med. Chem., 32:2092-2103 (1989).							
LCM		Brandes et al., "Correlation of the Antiproliferative Action of Diphenylmethane- Derivative Antiestrogen Binding Site Ligands with Antagonism of Histamine Binding but not of Protein Kinase C-mediated Phosphorylation," <u>Cancer. Res.</u> , 48:3954-3958 (1988).							
LCM	Carini et al., "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of								
LCM		Emmens, "Halogen-Substituted Oestrogens Related to Triphenylethylene," <u>J.</u> Endocrinol., Dodds, E.C.; Williams, P.C.; eds., <u>5</u> :170-173 (1946-48).							
LCM		Francis et al., "The Development of Diphosphonates as Significant Health Care Products," J. Chem. Educ., 55(12):760-766 (1978).							
μМ		Frolik et al., "Time-Dependent Changes in Biochemical Bone Markers and Serum Cholesterol in Ovariectomized Rats: Effects of Raloxifene HCl, Tamoxifen, Estrogen, and Alendronate," Bone, 18(6): 621-627 (1996).							

EXAMINER	Leight	Date Considered 9	30-02
----------	--------	-------------------	-------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



OMB No. 0651-0011 Page 2 of 4

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.: 235.0006 0102	Serial No.: Unknown		
	Confirmation No.:		
Applicant(s): Peter C. Ruenitz			

Filing Date: On Even Date Herewith Group: 1623

LCM	Frost, "Bone Histomorphometry: Analysis of Trabecular Bone Dynamics," <u>Bone Histomorphometry: Techniques and Interpretation</u> , Recker, ed., Boca Raton, FL, CRC Press, pp. 109-131 (1983).
LCM	Fujisaki et al., "Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. V. Biological Disposition and Targeting Characteristics of Osteotropic Estradiol," <i>Biol. Pharm. Bull.</i> , 20(11):1183-1187 (1997).
LCM	Hyder et al., "Estrogen Action in Target Cells: Selective Requirements for Activation of Different Hormone Response Elements," Mol. Cell. Endocrinol., 112: 35-43 (1995).
LCM	Jimenez et al., "Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats," Endocrinology, 138(5):1794-1800 (1997).
LCM	Jordan, "Biochemical Pharmacology of Antiestrogen Action," <u>Pharmacol. Rev.</u> , <u>36</u> (4):245-276 (1984).
LCM	Jordan et al., "Geometric Isomers of Substituted Triphenylethylenes and Antiestrogen Action," <u>Endocrinology</u> , 108(4):1353-1361 (1981).
LCM	Ke et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Chlosterol, and Uterine Histology in the Ovariectomized Rat Model," <u>Bone</u> , 20(1):31-39 (1997).
LCM	Ke et al., "Droloxifene, a New Estrogen Antagonist/Agonist, Prevents Bone Loss in Ovariectomized Rats," <u>Endocrinology</u> , 136(6):2435-2441 (1995).
LCM	Killackey et al., "Endometrial Adenocarcinoma in Breast Cancer Patients Receiving Antiestrogens," <u>Cancer Treat. Rep., 69(2):237-238 (1984).</u>
LCM	Kohno et al., "Anti-estrogen Activity in the Yeast Transcription System: Estrogen Receptor Mediated Agonist Response," <u>Steroids</u> , <u>59</u> :572-578 (1994).
LCM	Kraft et al. "3-Hydroxytriarylethylene Oxyacetic Acid: a Configurationally Defined Estrogen Antagonist in MCF-7 Cells," 214th ACS National Meeting, Las Vegas NV, September 7-11, Abstract No. 202 (1997).
LCM	Kraft et al., "Carboxylic Acid Analogues of Tamoxifen: (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen Receptor Affinity and Estrogen Antagonist Effects in MCF-7 Cells," J. Med. Chem., 42(16):3126-33 (1999) (entered into ACS CAPLUS electronic database on 26 July 1999).
LCM	Kuiper et al., "Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β," <u>Endocrinology</u> , <u>138</u> (3):863-870 (1997).

EXAMINER Light Date Considered 9-30-02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



OMB No. 0651-0011 Page 3 of 4

INFORMATION
DISCLOSURE
STATEMENT

Atty. Docket No.: 235.0006 0102	Serial No.: Unknown
	Confirmation No.:
Applicant(s): Peter C. Ruenitz	
Filing Date: On Even Date Herewith	Group: 1623

LCM	Love et al., "Bone Mineral Density in Women with Breast Cancer Treated with Adjuvant Tamoxifen for at least Two Years," <u>Breast Cancer Res. Treat.</u> , <u>12</u> :297-302 (1988).
LCM	Lundeen et al., "Characterization of the Ovariectomized Rat Model for the Evaluation of Estrogen Effects on Plasma Cholesterol Levels," <u>Endocrinology</u> , <u>138</u> (4):1552-1558 (1997).
LCM	Moon et al., "Dose-Dependent Effects of Tamoxifen on Long Bones in Growing Rats: Influence of Ovarian Status," <u>Endocrinology</u> , 129(3):1568-1574 (1991).
LCM	Onoe et al., "Expression of Estrogen Recpetor β in Rat Bone," Endocrinology, 138(10):4509-4512 (1997).
LCM	Ruenitz, "Female Sex Hormones and Analogs," <u>Burger's Medicinal Chemistry</u> and <u>Drug Discovery</u> , 5 th Edition, Wolff, ed., Vol. 4, New York, John Wiley & Sons, Ch. 57, pp. 553-587 (1997).
LCM	Ruenitz et al., "Specific Bone-Protective Effects of Metabolites/Derivatives of Tamoxifen and Clomiphene in Ovariectomized Rats," <u>Bone</u> , <u>23</u> (6):537-542 (1998).
LCM	Ruenitz et al., "Acidic Metabolites of Tamoxifen Aspects of Formation and Fate in the Female Rat," <u>Drug Metab. Dispos.</u> , 23(9):993-998 (1995).
LCM	Ruenitz et al., "Estrogenic Triarylethylene Acetic Acids: Effect of Structural Variation on Estrogen Receptor Affinity and Estrogenic Potency and Efficacy in MCF-7 Cells," J. Med. Chem., 39:4853-4859 (1996).
LCM	Ruenitz et al., "Estrogenic Tamoxifen Derivatives: Categorization of Intrinsic Estrogenicity in MCF-7 Cells," <u>J. Steroid Biochem. Mol. Biol.</u> , <u>63</u> (4-6):203-209 (1997).
LCM	Sato et al., "Raloxifene, Tamoxifen, Nafoxidine, or Estrogen Effects on Reproductive and Nonreproductive Tissues in Ovariectomized Rats," <u>FASEB J.</u> , <u>10</u> :905-912 (1996).
LCM	Seoud et al., "Gynecologic Tumors in Tamoxifen-Treated Women With Breast Cancer," Obstet. Gynecol., 82(2):165-169 (1993).
LCM	Shelby et al., "Assessing Environmental Chemicals for Estrogenicity Using a Combination of <i>In Vitro</i> and <i>In Vivo</i> Assays," Environ. Health Perspect., 104(12):1296-1300 (1996).

EXAMINER	Light	Date Considered	9-30-02
----------	-------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[^] INFORMATION	Atty. Docket No.: 235.0006 0102	Serial No.: Unknown	
DISCLOSURE	Confirmation		
STATEMENT	Applicant(s): Peter C. Ruenitz		
84	Filing Date: On Even Date Herewith	Group: 1623	

LCM	(ABSTRACT) Shen et al., "Bone Protective Effects of Nonsteroidal Estrogen Receptor (ER) Ligands in Ovariectomized Rats," <u>J. Bone Miner. Res 1997</u> <u>Program & Abstracts</u> , 19 th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, OH, <u>12</u> (1): pg. S354, No. F514, Sept. 10-14 (1997).				
LCM	Soto et al., "The E-SCREEN Assay as a Tool to Identify Estrogens: An Update on Estrogenic Environmental Pollutants," <u>Environ. Health Perspectives</u> , <u>103</u> (Supp. 7):113-122 (1995).				
LCM	Soto et al., "The Role of Estrogens on the Proliferation of Human Breast Tumor Cells (MCF-7)," <u>J. Steroid Biochem.</u> , 23(1):87-94 (1985).				
LCM	Wang et al., "Molecular Effects of Genistein on Estrogen Receptor Mediated Pathways," Carcinogenesis, 17(2):271-275 (1996).				
LCM	Williams et al., "Effects of Estrogen and Tamoxifen on Serum Osteocalcin Levels in Ovariectomized Rats," <u>Bone Mineral.</u> , 14:205-220 (1991).				
LCM	Willson et al., "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone," Endocrinology, 138(9):3901-3911 (1997).				
LCM	Wilson et al., "Estrogen Receptor Affinity and Effects on MCF-7 Cell Growth of Triarylethylene Carboxylic Acids Related to Tamoxifen," <u>J. Steroid. Biochem.</u> Molec. Biol., 42(6):613-616 (1992).				
LCM	Wronski et al., "Skeletal Effects of Withdrawal of Estrogen and Diphosphonate Treatment in Ovarectomized Rats," <u>Calcif. Tissue Int., 53</u> :210-216 (1993).				
LCM	Wronski et al., "Estrogen Treatment Prevents Osteopenia and Depresses Bone Turnover in Ovariectomized Rats," <u>Endocrinology</u> , 123(2):681-686 (1988).				
LCM	Young et al., "A Short-Term Comparison of the Effects of Clomiphene Citrate and Conjugated Equine Estrogen in Menopausal/Castrate Women," Int. J. Fertil., 36(3):167-171 (1991).				
EXAMINER	Light 9-30-02				
*Examiner: Initial if	citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in				

conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-FB-A820 Patent and Trademark Office, U.S. Department of Commerce
(Also form PTO-1449)

OMB No. 0651-0011 Page 1 of 1

INFORMATION .		Att	Atty. Docket No.: 235.0006 0102			Serial No.: 09/981,617			
DISCLOSURE STATEMENT				Confirmation No.: 6396					396
			Ap	plicant(s): Pe	eter C. Ruenitz				4
		4	Fili	ing Date: On	Even Date Herewith	Grou	Group: 1623 🕏		
(PA	JAN (7 2002	U.S	S. PATENT I	OCUMENTS				EIN
Examiner Initial	PE TH	DEMARIO ument Numb	er	Date	Name	Class	SubClass	Filing Appro	Date If priate
		NONE							
							<u> </u>		
		F	ORE	IGN PATEN	T DOCUMENTS				
		Document Numb	er	Date	Country	Class	SubClass	Trans	
		NONE					<u> </u>	Yes	No
	<u> </u>	NONE					<u> </u>	<u> </u>	
(OTHE	R DOCUMENT	S (In	cluding Autl	hors, Title, Date, Per	tinent I	Papers, et	c.)	
LCM	Rubin et al., "Identification of New Triarylethylene Oxyalkanoic Acid Analogues							ies	
						-			
EXAMI	NER	Leigh A	·	-	Date Considered	9-30	0-02		
*Evaminare	Initial if	sitation considered who	4han an	not citation is in co	onformance with MPFP 600. I	row line th	rough citation	if not in	, I

conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-FB-A820 Patent and Trademark Office, U.S. Department of Commerce (Also form PTO-1449)